{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T23:17:00Z","timestamp":1777763820742,"version":"3.51.4"},"reference-count":103,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["13GW0338B"],"award-info":[{"award-number":["13GW0338B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013326","name":"Stiftung Mercator GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006360","name":"Bundesministerium fur Wirtschaft und Energie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.kint.2022.08.025","type":"journal-article","created":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T17:46:44Z","timestamp":1662918404000},"page":"1392-1408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["In\u00a0vitro and in\u00a0vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein\u2013Barr virus\u2013associated post-transplant lymphoproliferative disorder"],"prefix":"10.1016","volume":"102","author":[{"given":"Constantin J.","family":"Thieme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malissa","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Wehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Anft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Amini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Bl\u00e0zquez-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrik","family":"Stervbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikalai","family":"Nienen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Barbara","family":"Stittrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiota","family":"Zgoura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Viebahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schmueck-Henneresse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timm H.","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toralf","family":"Roch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Babel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2022.08.025_bib1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fonc.2018.00211","article-title":"Epstein-Barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population: an update","volume":"8","author":"Smatti","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.kint.2022.08.025_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13652","article-title":"Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Allen","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2022.08.025_bib3","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","article-title":"Latency and lytic replication in Epstein\u2013Barr virus-associated oncogenesis","volume":"17","author":"M\u00fcnz","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.kint.2022.08.025_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fonc.2019.00081","article-title":"Viral-targeted strategies against EBV-associated lymphoproliferative diseases","volume":"9","author":"Hui","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.kint.2022.08.025_bib5","doi-asserted-by":"crossref","first-page":"15088","DOI":"10.1038\/nrdp.2015.88","article-title":"Post-transplant lymphoproliferative disorders","volume":"2","author":"Dharnidharka","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.kint.2022.08.025_bib6","doi-asserted-by":"crossref","first-page":"e00238","DOI":"10.1128\/JVI.00238-19","article-title":"Mechanisms of B-cell oncogenesis induced by Epstein-Barr virus","volume":"93","author":"Saha","year":"2019","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.kint.2022.08.025_bib7","doi-asserted-by":"crossref","first-page":"12616","DOI":"10.1073\/pnas.94.23.12616","article-title":"Inhibition of ubiquitin\/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1","volume":"94","author":"Levitskaya","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2022.08.025_bib8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc.2016.92","article-title":"Epstein-Barr virus: more than 50 years old and still providing surprises","volume":"16","author":"Young","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.kint.2022.08.025_bib9","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus particles in cultured lymphoblasts from Burkitt\u2019s lymphoma","volume":"283","author":"Epstein","year":"1964","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.08.025_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-transplantation lymphoproliferative disorders in adults","volume":"378","author":"Dierickx","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.025_bib11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2022.08.025_bib12","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.kint.2020.10.018","article-title":"Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period","volume":"99","author":"Blosser","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.08.025_bib13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.kint.2018.06.009","article-title":"Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients","volume":"94","author":"Francis","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.08.025_bib14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/00007890-200104270-00010","article-title":"Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American pediatric renal transplant cooperative study (NAPRTCS)","volume":"71","author":"Dharnidharka","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2022.08.025_bib15","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1046\/j.0007-1323.2001.01924.x","article-title":"Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients","volume":"88","author":"Libertiny","year":"2001","journal-title":"Br J Surg"},{"key":"10.1016\/j.kint.2022.08.025_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.TP.0000165098.49658.F3","article-title":"Lymphoproliferative disease after renal transplantation in Australia and New Zealand","volume":"80","author":"Faull","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2022.08.025_bib17","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.V87.6.2594.bloodjournal8762594","article-title":"The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation","volume":"87","author":"Lucas","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.kint.2022.08.025_bib18","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMra032015","article-title":"Persistence of the Epstein-Barr virus and the origins of associated lymphomas","volume":"350","author":"Thorley-Lawson","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.025_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1600-6135.2003.00274.x","article-title":"Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients","volume":"4","author":"Bustami","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2022.08.025_bib20","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1200\/JCO.2008.20.0857","article-title":"Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center","volume":"27","author":"Knight","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2022.08.025_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/TP.0b013e31823ae7db","article-title":"Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients","volume":"93","author":"Sampaio","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2022.08.025_bib22","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1111\/j.1600-6143.2007.01972.x","article-title":"Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab","volume":"7","author":"Kirk","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2022.08.025_bib23","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2022.08.025_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ajh.21911","article-title":"Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States","volume":"86","author":"Quinlan","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.kint.2022.08.025_bib25","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1097\/TP.0000000000002269","article-title":"Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder","volume":"102","author":"Zimmermann","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2022.08.025_bib26","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/01.tp.0000169035.10572.c6","article-title":"Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil","volume":"80","author":"Funch","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2022.08.025_bib27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1034\/j.1399-3046.2002.00021.x","article-title":"Mycophenolate, tacrolimus and posttransplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study","volume":"6","author":"Dharnidharka","year":"2002","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.kint.2022.08.025_bib28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.canlet.2019.10.045","article-title":"Immune activation, immune senescence and levels of Epstein Barr virus in kidney transplant patients: impact of mTOR inhibitors","volume":"469","author":"Petrara","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.kint.2022.08.025_bib29","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/tri.13982","article-title":"Risk factors for Epstein\u2013Barr virus reactivation after renal transplantation: results of a large, multi-centre study","volume":"34","author":"Blazquez-Navarro","year":"2021","journal-title":"Transplant Int"},{"key":"10.1016\/j.kint.2022.08.025_bib30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","article-title":"Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder","volume":"11","author":"Reshef","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2022.08.025_bib31","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/00007890-200104270-00012","article-title":"Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients","volume":"71","author":"Tsai","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2022.08.025_bib32","first-page":"106","article-title":"Malignant lymphomas in transplantation patients","volume":"1","author":"Penn","year":"1969","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2022.08.025_bib33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2010.08160.x","article-title":"Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients\u2014BCSH and BTS guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.kint.2022.08.025_bib34","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/cid\/cit391","volume":"57","author":"Styczynski","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.kint.2022.08.025_bib35","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(84)90994-2","article-title":"Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy","volume":"323","author":"Starzl","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.08.025_bib36","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/tri.12375","article-title":"CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality","volume":"27","author":"Rabot","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2022.08.025_bib37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/TP.0b013e3181761659","article-title":"Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder","volume":"86","author":"Swinnen","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2022.08.025_bib38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.kint.2022.08.025_bib39","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood.V100.5.1755.h81702001755_1755_1764","article-title":"B\u00a0cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells","volume":"100","author":"Moosmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.kint.2022.08.025_bib40","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3389\/fimmu.2019.01148","article-title":"Comprehensive characterization of a next-generation antiviral T-cell product and feasibility for application in immunosuppressed transplant patients","volume":"10","author":"Amini","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2022.08.025_bib41","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3389\/fimmu.2019.00593","article-title":"The role of pre-existing cross-reactive central memory CD4 T-cells in vaccination with previously unseen influenza strains","volume":"10","author":"Nienen","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2022.08.025_bib42","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1093\/bioinformatics\/btv309","article-title":"IMSEQ\u2014a fast and error aware approach to immunogenetic sequence analysis","volume":"31","author":"Kuchenbecker","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.kint.2022.08.025_bib43","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1038\/s41467-019-13055-y","article-title":"Automated optimized parameters for T-distributed stochastic neighbor embedding improve visualization and analysis of large datasets","volume":"10","author":"Belkina","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2022.08.025_bib44","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry A"},{"key":"10.1016\/j.kint.2022.08.025_bib45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.kint.2022.08.025_bib47","series-title":"On Measures of Entropy and Information","author":"R\u00e9nyi","year":"1961"},{"key":"10.1016\/j.kint.2022.08.025_bib48","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1086\/282436","article-title":"Measurement of \u201coverlap\u201d in comparative ecological studies","volume":"100","author":"Horn","year":"1966","journal-title":"Am Nat"},{"key":"10.1016\/j.kint.2022.08.025_bib49","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.080068597","article-title":"The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in\u00a0vitro and in\u00a0vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders","volume":"97","author":"Majewski","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2022.08.025_bib50","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.38.1.126","article-title":"Effect of mycophenolic acid on Epstein-Barr virus infection of human B lymphocytes","volume":"38","author":"Alfieri","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.kint.2022.08.025_bib51","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","article-title":"Biological consequences of MHC-II expression by tumor cells in cancer","volume":"25","author":"Axelrod","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.kint.2022.08.025_bib52","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/JVI.02183-15","article-title":"The missing link in Epstein-Barr virus immune evasion: the BDLF3 gene induces ubiquitination and downregulation of major histocompatibility complex class I (MHC-I) and MHC-II","volume":"90","author":"Quinn","year":"2016","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.kint.2022.08.025_bib53","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood-2007-07-101907","article-title":"Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines","volume":"111","author":"Bhaduri-McIntosh","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.kint.2022.08.025_bib54","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/nm1292","article-title":"Direct access to CD4+ T cells specific for defined antigens according to CD154 expression","volume":"11","author":"Frentsch","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2022.08.025_bib55","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood-2006-11-056168","article-title":"Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities","volume":"110","author":"Wolfl","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.kint.2022.08.025_bib56","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4049\/jimmunol.167.3.1313","article-title":"4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy","volume":"167","author":"Cannons","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2022.08.025_bib57","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","article-title":"HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells","volume":"107","author":"Betts","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.kint.2022.08.025_bib58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2567.2011.03476.x","article-title":"Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4+ and CD8+ polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins","volume":"134","author":"Ning","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.kint.2022.08.025_bib59","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2022.08.025_bib60","doi-asserted-by":"crossref","first-page":"100092","DOI":"10.1016\/j.xcrm.2020.100092","article-title":"Robust T cell response toward spike, membrane, and nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients","volume":"1","author":"Thieme","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.kint.2022.08.025_bib61","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.4049\/jimmunol.1201090","article-title":"A\u00a0converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3+ Treg","volume":"189","author":"Schoenbrunn","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2022.08.025_bib62","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1182\/blood-2002-11-3577","article-title":"Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines","volume":"101","author":"Geginat","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.kint.2022.08.025_bib63","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1084\/jem.173.3.647","article-title":"Interferon \u03b3 and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes","volume":"173","author":"Barth","year":"1991","journal-title":"J\u00a0Exp Med"},{"issue":"suppl 3","key":"10.1016\/j.kint.2022.08.025_bib64","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2022.08.025_bib65","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF01060885","article-title":"Dose dependent pharmacokinetics of prednisone and prednisolone in man","volume":"9","author":"Rose","year":"1981","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"key":"10.1016\/j.kint.2022.08.025_bib66","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1034\/j.1399-0012.2000.140201.x","article-title":"Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity","volume":"14","author":"Kahan","year":"2000","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2022.08.025_bib67","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/01.ftd.0000189898.23931.3f","article-title":"Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients","volume":"28","author":"Akhlaghi","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.kint.2022.08.025_bib68","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/FTD.0b013e3180318c35","article-title":"Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus","volume":"29","author":"Patel","year":"2007","journal-title":"Therap Drug Monitor"},{"key":"10.1016\/j.kint.2022.08.025_bib69","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.20.01709","article-title":"Adoptive T-cell therapy for Epstein-Barr virus-related lymphomas","volume":"39","author":"Heslop","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2022.08.025_bib70","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1128\/jvi.62.3.894-901.1988","article-title":"Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains","volume":"62","author":"Murray","year":"1988","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.kint.2022.08.025_bib71","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1073\/pnas.92.13.5875","article-title":"Immortalization of human primary B lymphocytes in\u00a0vitro with DNA","volume":"92","author":"Kempkes","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2022.08.025_bib72","article-title":"Single-cell RNA-seq reveals transcriptomic heterogeneity mediated by host-pathogen dynamics in lymphoblastoid cell lines","volume":"10","author":"Sorelle","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.kint.2022.08.025_bib73","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/ajt.12858","article-title":"A\u00a0comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors","volume":"14","author":"Fink","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2022.08.025_bib74","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/jcp.50.11.911","article-title":"Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas","volume":"50","author":"Brink","year":"1997","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.kint.2022.08.025_bib75","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.4049\/jimmunol.0713607","article-title":"Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition","volume":"182","author":"Brooks","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2022.08.025_bib76","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jcv.2011.06.013","article-title":"Lytic and latent EBV gene expression in transplant recipients with and without post-transplant lymphoproliferative disorder","volume":"52","author":"Kroll","year":"2011","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.kint.2022.08.025_bib77","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1038\/s41598-017-09798-7","article-title":"Lytic EBV infection investigated by detection of soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD","volume":"7","author":"Habib","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2022.08.025_bib78","first-page":"621","article-title":"Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease","volume":"9","author":"Montone","year":"1996","journal-title":"Mod Pathol"},{"issue":"suppl 1","key":"10.1016\/j.kint.2022.08.025_bib79","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1093\/annonc\/5.suppl_1.S113","article-title":"Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin\u2019s lymphomas","volume":"5","author":"Rea","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.kint.2022.08.025_bib80","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.1128\/JVI.76.16.8179-8188.2002","article-title":"The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules","volume":"76","author":"Keating","year":"2002","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.kint.2022.08.025_bib81","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.virol.2010.01.002","article-title":"Cellular factors associated with latency and spontaneous Epstein\u2013Barr virus reactivation in B-lymphoblastoid cell lines","volume":"400","author":"Davies","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.kint.2022.08.025_bib82","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/eji.1830121206","article-title":"Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. III. Establishment of HLA-restricted cytotoxic T cell lines using interleukin 2","volume":"12","author":"Wallace","year":"1982","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.kint.2022.08.025_bib83","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/cimm.2001.1760","article-title":"Functional CD4+ and CD8+ T-cell responses induced by autologous mitomycin C treated Epstein\u2013Barr virus transformed lymphoblastoid cell lines","volume":"208","author":"Meij","year":"2001","journal-title":"Cell Immunol"},{"key":"10.1016\/j.kint.2022.08.025_bib84","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.4049\/jimmunol.0902850","article-title":"Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors","volume":"184","author":"Merlo","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2022.08.025_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004068","article-title":"Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders","volume":"10","author":"Linnerbauer","year":"2014","journal-title":"PLOS Pathog"},{"key":"10.1016\/j.kint.2022.08.025_bib86","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/1471-2407-6-265","article-title":"Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells","volume":"6","author":"Markasz","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.kint.2022.08.025_bib87","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00204-014-1247-1","article-title":"Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update","volume":"88","author":"Staatz","year":"2014","journal-title":"Arch Toxicol"},{"issue":"2 suppl","key":"10.1016\/j.kint.2022.08.025_bib88","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","article-title":"Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection","volume":"80","author":"Allison","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2022.08.025_bib89","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.4049\/jimmunol.0803218","article-title":"Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation","volume":"182","author":"Horst","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2022.08.025_bib90","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/j.1600-6143.2009.02832.x","article-title":"The multifunctional role of mTOR in innate immunity: implications for transplant immunity","volume":"9","author":"S\u00e4emann","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2022.08.025_bib91","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1182\/blood-2002-10-3001","article-title":"Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease","volume":"101","author":"Meij","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.kint.2022.08.025_bib92","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/eji.201343751","article-title":"The who\u2019s who of T-cell differentiation: human memory T-cell subsets","volume":"43","author":"Mahnke","year":"2013","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.kint.2022.08.025_bib93","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.4049\/jimmunol.1103763","article-title":"Preferential expansion of human virus-specific multifunctional central memory T cells by partial targeting of the IL-2 receptor signaling pathway: the key role of CD4+ T cells","volume":"188","author":"Schmueck","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2022.08.025_bib94","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR regulates memory CD8 T-cell differentiation","volume":"460","author":"Araki","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.kint.2022.08.025_bib95","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1097\/TP.0000000000002776","article-title":"The identity card of T cells\u2014clinical utility of T-cell receptor repertoire analysis in transplantation","volume":"103","author":"Babel","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2022.08.025_bib96","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1126\/science.1076064","article-title":"Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense","volume":"298","author":"Messaoudi","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.kint.2022.08.025_bib97","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/TP.0b013e3181bca422","article-title":"Inhibition of polyomavirus BK-specific T-cell responses by immunosuppressive drugs","volume":"88","author":"Egli","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2022.08.025_bib98","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ki.2015.215","article-title":"A\u00a0revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients","volume":"88","author":"Weist","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.08.025_bib99","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/00007890-200109270-00017","article-title":"Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients","volume":"72","author":"Savoldo","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2022.08.025_bib100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.immuni.2020.07.002","article-title":"Anti-inflammatory roles of glucocorticoids are mediated by Foxp3+ regulatory T cells via a miR-342-dependent mechanism","volume":"53","author":"Kim","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.kint.2022.08.025_bib101","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1097\/01.tp.0000290232.65830.e7","article-title":"A\u00a0quantitative assay for Epstein-Barr virus\u2013specific immunity shows interferon-\u03b3 producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease","volume":"84","author":"Guppy","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2022.08.025_bib102","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.4049\/jimmunol.158.9.4045","article-title":"Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines","volume":"158","author":"Beatty","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2022.08.025_bib103","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/ajt.13503","article-title":"Epstein-Barr virus modulates host cell microRNA-194 to promote IL-10 production and B lymphoma cell survival","volume":"15","author":"Harris-Arnold","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2022.08.025_bib104","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ymthe.2020.09.011","article-title":"CRISPR-Cas9-edited tacrolimus-resistant antiviral T cells for advanced adoptive immunotherapy in transplant recipients","volume":"29","author":"Amini","year":"2021","journal-title":"Mol Ther"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253822007141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253822007141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:55:30Z","timestamp":1777474530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253822007141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":103,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0085253822007141"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2022.08.025","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vitro and in\u00a0vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein\u2013Barr virus\u2013associated post-transplant lymphoproliferative disorder","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2022.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}